

# Secondary Progressive Multiple Sclerosis Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

<https://marketpublishers.com/r/S671228E538EEN.html>

Date: December 2020

Pages: 114

Price: US\$ 3,000.00 (Single User License)

ID: S671228E538EEN

## Abstracts

### SUMMARY

Further key aspects of the report indicate that:

Chapter 1: Research Scope: Product Definition, Type, End-Use & Methodology

Chapter 2: Global Industry Summary

Chapter 3: Market Dynamics

Chapter 4: Global Market Segmentation by region, type and End-Use

Chapter 5: North America Market Segmentation by region, type and End-Use

Chapter 6: Europe Market Segmentation by region, type and End-Use

Chapter 7: Asia-Pacific Market Segmentation by region, type and End-Use

Chapter 8: South America Market Segmentation by region, type and End-Use

Chapter 9: Middle East and Africa Market Segmentation by region, type and End-Use.

Chapter 10: Market Competition by Companies

Chapter 11: Market forecast and environment forecast.

Chapter 12: Industry Summary.

The global Secondary Progressive Multiple Sclerosis Drug market has the potential to grow with xx million USD with growing CAGR in the forecast period from 2021f to 2026f. Factors driving the market for @@@@ are the significant development of demand and improvement of COVID-19 and geo-economics.

Based on the type of product, the global Secondary Progressive Multiple Sclerosis Drug market segmented into

Inebilizumab

GLX-1112

DC-TAB

Etomoxir

IB-MS

Others

Based on the end-use, the global Secondary Progressive Multiple Sclerosis Drug market classified into

Hospital

Clinic

Others

Based on geography, the global Secondary Progressive Multiple Sclerosis Drug market segmented into

North America [U.S., Canada, Mexico]

Europe [Germany, UK, France, Italy, Rest of Europe]

Asia-Pacific [China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific]

South America [Brazil, Argentina, Rest of Latin America]

Middle East & Africa [GCC, North Africa, South Africa, Rest of Middle East and Africa]

And the major players included in the report are

AB Science SA

Actelion Ltd

Biogen, Inc.

F. Hoffmann-La Roche Ltd.

Genzyme Corporation

Glialogix, Inc.

Immune Response BioPharma, Inc.

Innate Immunotherapeutics Ltd

Kyorin Pharmaceutical Co., Ltd.

Mallinckrodt Plc

MedDay SA

MedImmune, LLC

Merck KGaA

Meta-IQ ApS

Novartis AG

Opexa Therapeutics, Inc.

Xenetic Biosciences (UK) Limited

## Contents

### 1 RESEARCH SCOPE

- 1.1 Research Product Definition
- 1.2 Research Segmentation
  - 1.2.1 Product Type
  - 1.2.2 Main product Type of Major Players
- 1.3 Demand Overview
- 1.4 Research Methodology

### 2 GLOBAL SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS DRUG INDUSTRY

- 2.1 Summary about Secondary Progressive Multiple Sclerosis Drug Industry
- 2.2 Secondary Progressive Multiple Sclerosis Drug Market Trends
  - 2.2.1 Secondary Progressive Multiple Sclerosis Drug Production & Consumption Trends
  - 2.2.2 Secondary Progressive Multiple Sclerosis Drug Demand Structure Trends
- 2.3 Secondary Progressive Multiple Sclerosis Drug Cost & Price

### 3 MARKET DYNAMICS

- 3.1 Manufacturing & Purchasing Behavior in 2020
- 3.2 Market Development under the Impact of COVID-19
  - 3.2.1 Drivers
  - 3.2.2 Restraints
  - 3.2.3 Opportunity
  - 3.2.4 Risk

### 4 GLOBAL MARKET SEGMENTATION

- 4.1 Region Segmentation (2017 to 2021f)
  - 4.1.1 North America (U.S., Canada and Mexico)
  - 4.1.2 Europe (Germany, UK, France, Italy, Rest of Europe)
  - 4.1.3 Asia-Pacific (China, India, Japan, South Korea, Southeast Asia, Australia, Rest of Asia Pacific)
  - 4.1.4 South America (Brazil,, Argentina, Rest of Latin America)
  - 4.1.5 Middle East and Africa (GCC, North Africa, South Africa, Rest of Middle East and

Africa)

#### 4.2 Product Type Segmentation (2017 to 2021f)

4.2.1 Inebilizumab

4.2.2 GLX-1112

4.2.3 DC-TAB

4.2.4 Etomoxir

4.2.5 IB-MS

4.2.6 Others

#### 4.3 Consumption Segmentation (2017 to 2021f)

4.3.1 Hospital

4.3.2 Clinic

4.3.3 Others

## **5 NORTH AMERICA MARKET SEGMENT**

#### 5.1 Region Segmentation (2017 to 2021f)

5.1.1 U.S.

5.1.2 Canada

5.1.3 Mexico

#### 5.2 Product Type Segmentation (2017 to 2021f)

5.2.1 Inebilizumab

5.2.2 GLX-1112

5.2.3 DC-TAB

5.2.4 Etomoxir

5.2.5 IB-MS

5.2.6 Others

#### 5.3 Consumption Segmentation (2017 to 2021f)

5.3.1 Hospital

5.3.2 Clinic

5.3.3 Others

#### 5.4 Impact of COVID-19 in North America

## **6 EUROPE MARKET SEGMENTATION**

#### 6.1 Region Segmentation (2017 to 2021f)

6.1.1 Germany

6.1.2 UK

6.1.3 France

6.1.4 Italy

- 6.1.5 Rest of Europe
- 6.2 Product Type Segmentation (2017 to 2021f)
  - 6.2.1 Inebilizumab
  - 6.2.2 GLX-1112
  - 6.2.3 DC-TAB
  - 6.2.4 Etomoxir
  - 6.2.5 IB-MS
  - 6.2.6 Others
- 6.3 Consumption Segmentation (2017 to 2021f)
  - 6.3.1 Hospital
  - 6.3.2 Clinic
  - 6.3.3 Others
- 6.4 Impact of COVID-19 in Europe

## **7 ASIA-PACIFIC MARKET SEGMENTATION**

- 7.1 Region Segmentation (2017 to 2021f)
  - 7.1.1 China
  - 7.1.2 India
  - 7.1.3 Japan
  - 7.1.4 South Korea
  - 7.1.5 Southeast Asia
  - 7.1.6 Australia
  - 7.1.7 Rest of Asia Pacific
- 7.2 Product Type Segmentation (2017 to 2021f)
  - 7.2.1 Inebilizumab
  - 7.2.2 GLX-1112
  - 7.2.3 DC-TAB
  - 7.2.4 Etomoxir
  - 7.2.5 IB-MS
  - 7.2.6 Others
- 7.3 Consumption Segmentation (2017 to 2021f)
  - 7.3.1 Hospital
  - 7.3.2 Clinic
  - 7.3.3 Others
- 7.4 Impact of COVID-19 in Europe

## **8 SOUTH AMERICA MARKET SEGMENTATION**

- 8.1 Region Segmentation (2017 to 2021f)
  - 8.1.1 Brazil
  - 8.1.2 Argentina
  - 8.1.3 Rest of Latin America
- 8.2 Product Type Segmentation (2017 to 2021f)
  - 8.2.1 Inebilizumab
  - 8.2.2 GLX-1112
  - 8.2.3 DC-TAB
  - 8.2.4 Etomoxir
  - 8.2.5 IB-MS
  - 8.2.6 Others
- 8.3 Consumption Segmentation (2017 to 2021f)
  - 8.3.1 Hospital
  - 8.3.2 Clinic
  - 8.3.3 Others
- 8.4 Impact of COVID-19 in Europe

## **9 MIDDLE EAST AND AFRICA MARKET SEGMENTATION**

- 9.1 Region Segmentation (2017 to 2021f)
  - 9.1.1 GCC
  - 9.1.2 North Africa
  - 9.1.3 South Africa
  - 9.1.4 Rest of Middle East and Africa
- 9.2 Product Type Segmentation (2017 to 2021f)
  - 9.2.1 Inebilizumab
  - 9.2.2 GLX-1112
  - 9.2.3 DC-TAB
  - 9.2.4 Etomoxir
  - 9.2.5 IB-MS
  - 9.2.6 Others
- 9.3 Consumption Segmentation (2017 to 2021f)
  - 9.3.1 Hospital
  - 9.3.2 Clinic
  - 9.3.3 Others
- 9.4 Impact of COVID-19 in Europe

## **10 COMPETITION OF MAJOR PLAYERS**

## 10.1 Brief Introduction of Major Players

- 10.1.1 AB Science SA
- 10.1.2 Actelion Ltd
- 10.1.3 Biogen, Inc.
- 10.1.4 F. Hoffmann-La Roche Ltd.
- 10.1.5 Genzyme Corporation
- 10.1.6 Glialogix, Inc.
- 10.1.7 Immune Response BioPharma, Inc.
- 10.1.8 Innate Immunotherapeutics Ltd
- 10.1.9 Kyorin Pharmaceutical Co., Ltd.
- 10.1.10 Mallinckrodt Plc
- 10.1.11 MedDay SA
- 10.1.12 MedImmune, LLC
- 10.1.13 Merck KGaA
- 10.1.14 Meta-IQ ApS
- 10.1.15 Novartis AG
- 10.1.16 Opexa Therapeutics, Inc.
- 10.1.17 Xenetic Biosciences (UK) Limited

## 10.2 Secondary Progressive Multiple Sclerosis Drug Sales Date of Major Players (2017-2020e)

- 10.2.1 AB Science SA
- 10.2.2 Actelion Ltd
- 10.2.3 Biogen, Inc.
- 10.2.4 F. Hoffmann-La Roche Ltd.
- 10.2.5 Genzyme Corporation
- 10.2.6 Glialogix, Inc.
- 10.2.7 Immune Response BioPharma, Inc.
- 10.2.8 Innate Immunotherapeutics Ltd
- 10.2.9 Kyorin Pharmaceutical Co., Ltd.
- 10.2.10 Mallinckrodt Plc
- 10.2.11 MedDay SA
- 10.2.12 MedImmune, LLC
- 10.2.13 Merck KGaA
- 10.2.14 Meta-IQ ApS
- 10.2.15 Novartis AG
- 10.2.16 Opexa Therapeutics, Inc.
- 10.2.17 Xenetic Biosciences (UK) Limited

## 10.3 Market Distribution of Major Players

## 10.4 Global Competition Segmentation



## **11 MARKET FORECAST**

11.1 Forecast by Region

11.2 Forecast by Demand

11.3 Environment Forecast

11.3.1 Impact of COVID-19

11.3.2 Geopolitics Overview

11.3.3 Economic Overview of Major Countries

## **12 REPORT SUMMARY STATEMENT**

## List Of Tables

### LIST OF TABLES

Table Secondary Progressive Multiple Sclerosis Drug Product Type Overview
Table Secondary Progressive Multiple Sclerosis Drug Product Type Market Share List
Table Secondary Progressive Multiple Sclerosis Drug Product Type of Major Players
Table Brief Introduction of AB Science SA
Table Brief Introduction of Actelion Ltd
Table Brief Introduction of Biogen, Inc.
Table Brief Introduction of F. Hoffmann-La Roche Ltd.
Table Brief Introduction of Genzyme Corporation
Table Brief Introduction of Glialogix, Inc.
Table Brief Introduction of Immune Response BioPharma, Inc.
Table Brief Introduction of Innate Immunotherapeutics Ltd
Table Brief Introduction of Kyorin Pharmaceutical Co., Ltd.
Table Brief Introduction of Mallinckrodt Plc
Table Brief Introduction of MedDay SA
Table Brief Introduction of MedImmune, LLC
Table Brief Introduction of Merck KGaA
Table Brief Introduction of Meta-IQ ApS
Table Brief Introduction of Novartis AG
Table Brief Introduction of Opexa Therapeutics, Inc.
Table Brief Introduction of Xenetic Biosciences (UK) Limited
Table Products & Services of AB Science SA
Table Products & Services of Actelion Ltd
Table Products & Services of Biogen, Inc.
Table Products & Services of F. Hoffmann-La Roche Ltd.
Table Products & Services of Genzyme Corporation
Table Products & Services of Glialogix, Inc.
Table Products & Services of Immune Response BioPharma, Inc.
Table Products & Services of Innate Immunotherapeutics Ltd
Table Products & Services of Kyorin Pharmaceutical Co., Ltd.
Table Products & Services of Mallinckrodt Plc
Table Products & Services of MedDay SA
Table Products & Services of MedImmune, LLC
Table Products & Services of Merck KGaA
Table Products & Services of Meta-IQ ApS
Table Products & Services of Novartis AG
Table Products & Services of Opexa Therapeutics, Inc.

Table Products & Services of Xenetic Biosciences (UK) Limited

Table Market Distribution of Major Players

Table Global Major Players Sales Revenue (Million USD) 2017-2020e

Table Global Major Players Sales Revenue (Million USD) Share 2017-2020e

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Region 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Region 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) by Demand 2021f-2026f

Table Global Secondary Progressive Multiple Sclerosis Drug Market Forecast (Million USD) Share by Demand 2021f-2026f

## List Of Figures

### LIST OF FIGURES

Figure Global Secondary Progressive Multiple Sclerosis Drug Market Size under the Impact of COVID-19, 2017-2021f (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Region under the Impact of COVID-19, 2017-2021f (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Product Type under the Impact of COVID-19, 2017-2021f (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Market by Demand under the Impact of COVID-19, 2017-2021f (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Production by Region under the Impact of COVID-19, 2021-2026 (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Region under the Impact of COVID-19, 2021-2026 (USD Million)

Figure Global Secondary Progressive Multiple Sclerosis Drug Consumption by Type under the Impact of COVID-19, 2021-2026 (USD Million)

Figure North America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Asia-Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure South America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure U.S. Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Canada Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Mexico Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Germany Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure UK Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure France Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Italy Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Rest of Europe Market Size (USD Million) 2017-2021f and Year-over-year (YOY)

Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure China Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure India Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Japan Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure South Korea Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Southeast Asia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Australia Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Rest of Asia Pacific Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Brazil Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Argentina Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Rest of Latin America Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GCC Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure North Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY)

Growth (%) 2018-2021f

Figure South Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY)

Growth (%) 2018-2021f

Figure Rest of Middle East and Africa Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Inebilizumab Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure GLX-1112 Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure DC-TAB Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Etomoxir Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure IB-MS Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Hospital Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Clinic Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Others Segmentation Market Size (USD Million) 2017-2021f and Year-over-year (YOY) Growth (%) 2018-2021f

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of AB Science SA 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Actelion Ltd 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Biogen, Inc. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of F. Hoffmann-La Roche Ltd. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Genzyme Corporation 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Glialogix, Inc. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Immune Response BioPharma, Inc. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Innate Immunotherapeutics Ltd 2017-2020e



Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Kyorin Pharmaceutical Co., Ltd. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Mallinckrodt Plc 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedDay SA 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of MedImmune, LLC 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Merck KGaA 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Meta-IQ ApS 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Novartis AG 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Opexa Therapeutics, Inc. 2017-2020e

Figure Secondary Progressive Multiple Sclerosis Drug Sales Revenue (Million USD) of Xenetic Biosciences (UK) Limited 2017-2020e

## I would like to order

Product name: Secondary Progressive Multiple Sclerosis Drug Market Status and Trend Analysis 2017-2026 (COVID-19 Version)

Product link: <https://marketpublishers.com/r/S671228E538EEN.html>

Price: US\$ 3,000.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/S671228E538EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

